Klin Farmakol Farm. 2012;26(4):175-180

Respiratory syncytial virus - preventive and therapeutic options

František Kopřiva, Vladimír Mihál
Dětská klinika FN a LF UP Olomouc

Respiratory syncytial virus (RSV) is the most common respiratory pathogen in infants and young children worldwide. This review summarizes

the history, microbiology, epidemiology, pathophysiology, and clinical manifestations of this infection. RSV treatment modalities

are mainly supportive. Currently, immunoprophylaxis with palivizumab is the management strategy of choice.

Keywords: bronchiolitis, asthma, wheezing, humanized antibody, RSV immunoprophylaxis

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopřiva F, Mihál V. Respiratory syncytial virus - preventive and therapeutic options. Klin Farmakol Farm. 2012;26(4):175-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282: 1440-1446. Go to original source... Go to PubMed...
    2. Heikkinen T, Järvinen A. The common cold. Lancet 2003; 361: 51. Go to original source... Go to PubMed...
    3. Wright M, Piedimonte G. Respiratory Syncytial Virus Prevention and Therapy: Past, Present, and Future Pediatr Pulmonol 2011; 46: 324-347. Go to original source... Go to PubMed...
    4. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957; 66: 281-290. Go to original source...
    5. Chanock R, Finberg L. Recovery from infants with respirátory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children Am J Hyg 1957; 66: 291-300. Go to original source...
    6. Chanock RM, Kim HW, Vargosko AJ, Deleva A, Johnson KM, Cumming C, Parrott RH. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 1961; 176: 647-653. Go to original source... Go to PubMed...
    7. Simoes EA. Respiratory syncytial virus infection. The Lancet 1999; 354: 847-852. Go to original source... Go to PubMed...
    8. Čihař M. RSV infekce v dětském věku. Klinický průběh, možnosti léčby a imunoprofylaxe. Vakcinologie 2009; 3: 50-55.
    9. HallCB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986; 315: 77-81. Go to original source... Go to PubMed...
    10. Padman R, Bye MR, Schidlow DV, Zaeri N. Severe RSV bronchiolitis in an immunocompromised child. Clin Pediatr (Phila) 1985; 24: 719-721. Go to original source... Go to PubMed...
    11. Stephan V, Möller JC, Schauer U, Weigl JAI. RSV-Infektionen im Kindesalter. Pädiat Prax 2006; 68: 613-623.
    12. Figueras-Aloy J, Carbonell-Estrany X, Quero J, IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalisation in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004; 23: 815-820. Go to original source... Go to PubMed...
    13. Carbonell-Estrany X, Figueras-Aloy J, Law BJ. Infection Respiratonia Infantil por Virus Respiratorio, Pediatric Investigators Collaborative Network on Infections in Canada Study; Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004; 23 (Suppl 11): S193-201. Go to original source... Go to PubMed...
    14. OpenshawPJM, Tregoning JS. Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection. Clin Microbiol Rev 2005; 18: 541-555. Go to original source... Go to PubMed...
    15. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010; 23: 74-98. Go to original source... Go to PubMed...
    16. Henderson K, Hilliard T, Sherriff A. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 2005; 16: 386-392. Go to original source... Go to PubMed...
    17. Bont L, Steijn M, van Aalderen W. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis 2004; 23: 414-417. Go to original source... Go to PubMed...
    18. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501-1507. Go to original source... Go to PubMed...
    19. Sigurs N, Gustafsson PM, Bjarnason R. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171: 137-141. Go to original source... Go to PubMed...
    20. Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G. Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol 2002; 283: L494-L502. Go to original source... Go to PubMed...
    21. Tortorolo L, Langer A, Polidori G, Vento G, Stampachiacchere B, Aloe L, Piedimonte G. Neurotrophins overexpression in Loir airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 2005; 172: 233-237. Go to original source... Go to PubMed...
    22. Wedde-Beer K K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1143-L1150. Go to original source... Go to PubMed...
    23. Murray M, Webb MS, O'Callaghan C, Swarbrick AS, Milner AD. Respiratory status and allergy after bronchiolitis. Arch Dis Child 1992; 67: 482-487. Go to original source... Go to PubMed...
    24. Renz H. Neurotrophins in bronchial asthma. Respir Res 2001; 2: 265-268. Go to original source... Go to PubMed...
    25. Dobson JV, Stephens-Groff SM, McMahon SR. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 1998; 101: 361-342. Go to original source... Go to PubMed...
    26. De Boeck K, Van de Aa N, Van Lierde S. Respiratory syncytial virus bronchiolitis: a double-blind dexamathasone efficacy study. J. Pediatr 1997; 131: 919-921. Go to original source... Go to PubMed...
    27. Simoes E, Groothuis J, Carbonell-Estrany X. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatrics 2007; 151: 34-42. Go to original source... Go to PubMed...
    28. Greenes DS, Harper MB. Low risk of bacteremia in fibrile children with recognizable viral syndromes. Pediatr Infect Dis J 1999; 18: 258-261. Go to original source... Go to PubMed...
    29. Titus MO, Wright SW. Prevalence of serious bacterial infections in febrile infants with respiratory syncytial virus infection. Pediatrics 2003; 112: 282-284. Go to original source... Go to PubMed...
    30. Nasr SZ, Strouse PJ, Soskolne E, Maxvold NJ, Garver KA, Rubin BK. Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis. Chest 2001; 120: 203-208. Go to original source... Go to PubMed...
    31. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 2006; (3): CD005150. Go to original source...
    32. Hemming VG, Rodriguez W, Kim HW. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in nfants and young childern. Antimicrob. Agents. Chemother 1997; 31: 1882-1886. Go to original source... Go to PubMed...
    33. Johnson S, Oliver C, Prince GA. Developtment of humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis 1997; 176: 1215-1224. Go to original source... Go to PubMed...
    34. Abarca K, Jung E, Fernandez P, Zhao L, Harris B, Connor EM, Losonsky GA. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhancedpotency monoclonal antibody for the prevention of respirátory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009; 28: 267-272. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.